*To the Editor:* We would like to thank Llamas-Velasco et al[@bib1] for their interest in our research letter "Varicella-like exanthem as a specific COVID-19-associated skin manifestation: multicenter case series of 22 patients."[@bib2] They emphasize the need to use *Herpesviridae* family microarray polymerase chain reaction (PCR) on the vesicle fluid of patients with coronavirus disease 2019 (COVID-19) with papulovesicular eruptions to define the etiology of the exanthem by giving the example of 3 patients with laboratory-confirmed COVID-19. PCR demonstrated the presence of herpes simplex virus (HSV) 1, human herpes virus (HHV) 6, and Epstein-Barr virus (EBV) in patient 1, HSV-1 and HHV-7 in patient 2, and varicella-zoster virus (VZV) in patient 3.

We did not use vesicle fluid *Herpesviridae* family microarray PCR for logistical reasons in the case of 15 patients: 6 were in our intensive care unit, 4 in our infectious disease unit, and 5 were in isolation at home and evaluated by means of teledermatology. The remaining 7 patients were outpatients who had undergone a skin biopsy, and PCR was not used because true varicella could be ruled out on the grounds that the vesicles were not umbilicated, were scattered, and were often seen on the surface of papules; there were no pustules; and usually no itching. Furthermore, all of our patients had a previous history of varicella infection, and given the similarity of the lesions to those of varicella, we decided to use the term "varicella-like exanthem."

Lymphopenia was detected in only 8 patients, who were affected by more severe infection with severe acute respiratory syndrome coronavirus (SARS-CoV-2) and therefore possibly more susceptible to the development of a viral infection other than COVID-19.

In relation to the patients described by Llamas-Velasco et al,[@bib1] patient 1 can be diagnosed as having a classic Kaposi varicelliform eruption, which could be clinically excluded in our patients, and patient 3 can be diagnosed as having varicella with a purpuric component that was possibly due to alterations in the coagulation cascade or anticoagulant treatment administered to prevent COVID-19--related thromboembolic complications. We would have liked to have been able to see photographs of patient 2 to assess whether there were any similarities to the skin condition of our patients.

The detection of different viruses (HSV-1, HSV-2, HHV-6, HHV-7, VZV, and EBV) in the patients of Llamas-Velasco et al[@bib1] raises the question about whether they had a true viral infection other than COVID-19 or just a superinfection, because it is possible to speculate that the dysfunctional immune response associated with COVID-19 acts both systemically and locally in the skin, thus attracting viral bystanders. This can occur in patients with autoimmune bullous diseases receiving immunosuppressive treatment, as HSV-1 and HSV-2 DNA sequences have been demonstrated by means of blister fluid PCR.[@bib3] ^,^ [@bib4]

Finally, it is important to point out that neither we nor Llamas-Velasco et al[@bib1] assessed SARS-CoV-2 RNA, whereas SARS-CoV-2 RNA and the DNA of *Herpesviridae* family members should both be sought in COVID-19--associated skin lesions.
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